 Molecular Partners AG NASDAQ: MOLN shares are trading lower by 36.52 at 8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Vas. 